| GABSX | VSMAX | GABSX / VSMAX | |
| Total Expense Ratio | 1.38 | 0.05 | 2,760% |
| Annual Report Gross Expense Ratio | 1.38 | 0.05 | 2,760% |
| Fund Existence | 35 years | 26 years | - |
| Gain YTD | 13.922 | 14.588 | 95% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 3000 | 33% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.86B | 189B | 1% |
| Annual Yield % from dividends | 0.24 | 1.21 | 19% |
| Returns for 1 year | 16.58 | 22.58 | 73% |
| Returns for 3 years | 17.33 | 43.42 | 40% |
| Returns for 5 years | 2.61 | 35.11 | 7% |
| Returns for 10 years | 5.70 | 155.96 | 4% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BQLCX | 23.42 | 0.17 | +0.73% |
| Bright Rock Quality Large Cap Instl | |||
| GSPQX | 20.02 | 0.12 | +0.60% |
| Goldman Sachs US Eq Div and Premium C | |||
| GSIYX | 24.29 | N/A | N/A |
| Goldman Sachs GQG Ptnrs Intl Opps R6 | |||
| CCWIX | 21.73 | -0.15 | -0.69% |
| Baird Chautauqua International Gr Instl | |||
| RYOAX | 66.89 | -1.55 | -2.26% |
| Rydex Biotechnology H | |||